Drug intelligence / Profile preview

Bifidobacterium animalis subsp. lactis strain BB-12

Development stage: Unknown
Lead developer: Chr. Hansen
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

An investigational live biotherapeutic product containing the probiotic strain Bifidobacterium animalis subsp. lactis BB-12. It is being evaluated by Tanta University in a Phase 3 clinical trial (NCT05682807) as a potential adjuvant therapy for bronchopulmonary dysplasia (BPD) in preterm neonates. [1-2, 1-3, 1-13] The specific product used in the trial is Probio Tec BB12-Blend 30-IF, manufactured by Sandoz, which is provided as a lyophilized powder in packs. [1-2, 1-13] The therapy is administered orally once daily. [1-13, 1-14] The proposed mechanism involves modulation of the gut microbiome, which may regulate the gut-lung axis to reduce inflammation and subsequent lung damage characteristic of BPD. [3, 4]

Brand names: Probio Tec BB12-Blend 30-IF
Other names: probiotic formula-Tanta University-bronchopulmonary dysplasia

Beyond the preview

Go deeper on Bifidobacterium animalis subsp. lactis strain BB-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium animalis subsp. lactis strain BB-12.

Explore the full profile